MAP2K1 V60E
|
Melanoma
|
MAP2K1 V60E
|
Melanoma
|
vemurafenib Resistant: C3 – Early Trials
|
vemurafenib Resistant: C3 – Early Trials
|
MAP2K1 V60E
|
Melanoma
|
MAP2K1 V60E
|
Melanoma
|
dabrafenib Resistant: C3 – Early Trials
|
dabrafenib Resistant: C3 – Early Trials
|